Here is the useful way to think about Grace Science: it is a bet that the biology of one obscure enzyme, studied because a single child needed it, is worth turning into medicine - first for her disease, and then, maybe, for everyone else's.
In 2013, a Silicon Valley entrepreneur named Matt Wilsey learned that his daughter Grace had NGLY1 Deficiency, an ultra-rare genetic disorder. NGLY1 is a gene that encodes an enzyme - N-glycanase - which cells use to strip sugar tags off misfolded proteins so they can be cleared. When the gene doesn't work, the cellular housekeeping fails, and the consequences are severe: developmental delay, movement disorders, an inability to produce tears. At the time of Grace's diagnosis, she was one of roughly six known patients in the world.
Six patients is a number that tells you something important about the economics of medicine. No pharmaceutical company builds a drug program for six patients. The math does not work, the trials are nearly impossible to run, and the return does not exist. This is the standard, sensible reason that ultra-rare diseases go untreated. It is also the reason Grace Science exists - because the Wilseys declined to accept the math.
What they did first was not build a company. They built a foundation. The Grace Science Foundation spent five years running an open, collaborative global research network, funding scientists and, crucially, sharing the data. The idea was to compress the timeline that rare disease usually stretches across decades - to make research, in Wilsey's framing, faster, cheaper, and more collaborative than biology's default settings allow.
The foundation did the thing foundations are supposed to do and rarely manage: it produced enough real science that a company became the logical next step. In 2017, Wilsey co-founded Grace Science, LLC. His co-founder was not a typical biotech partner. It was Dr. Carolyn Bertozzi, a Stanford chemist whose work on the sugar molecules coating cells - glycobiology - would later win her the 2022 Nobel Prize in Chemistry. NGLY1, it turns out, is fundamentally a sugar-processing enzyme. Bertozzi's field and Grace's disease were describing the same molecular world.
The company's flagship is a gene therapy called GS-100. It is an AAV9 vector - a re-engineered virus that ferries a working copy of the NGLY1 gene into cells. The logic is direct: if the disease is a missing enzyme, deliver the instructions to make it. In 2024, Grace Science dosed its first patient in an open-label Phase 1/2/3 clinical trial. By the following disclosures, patients treated for at least 52 weeks were showing improvements in motor function and cognition - gains as concrete as sitting, standing, and walking with assistance, and improvements in attention and caregiver interaction.
Then came the regulatory momentum, which for a disease this rare is its own kind of evidence that the science is serious. The FDA selected GS-100 for its START pilot program, a scheme meant to accelerate rare-disease therapies. And in April 2026, the agency granted GS-100 Regenerative Medicine Advanced Therapy - RMAT - designation, a status reserved for treatments with early clinical evidence of addressing an unmet need. As Bertozzi put it, GS-100 is "the first and only treatment option in development specifically for NGLY1 Deficiency."
Here is where Grace Science gets genuinely interesting as a business, as opposed to merely moving as a story. The company describes itself as "agnostic to therapeutic modality and disease area." That is a careful way of saying it does not intend to be a one-disease company. The thesis is that deep understanding of the NGLY1 pathway - the same pathway that fails in Grace's disease - is a lever on far more common conditions. NGLY1 biology touches proteostasis, the cell's protein-quality-control system, which is implicated in both cancer and neurodegeneration. So alongside the gene therapy, Grace Science runs small-molecule programs and biomarker development aimed at oncology and neurodegenerative disease.
This is the part worth pausing on, because it inverts the usual assumption about rare disease. The conventional view treats ultra-rare conditions as charity cases - worthy, tragic, and commercially hopeless. Grace Science's wager is the opposite: that a rare disease is a keyhole. A single broken gene isolates a single biological mechanism with unusual clarity, and studying it can reveal machinery that everyone's cells share. The six patients are not just patients to be helped. They are, biologically, a controlled experiment nature has already run.
None of this makes the outcome certain. GS-100 is in trials, the data are early, and gene therapy is a field with a long history of humbling its optimists. But the structure of the thing is unusual and worth noticing: a company that started from a person rather than a molecule, that ran as an open foundation before it was a firm, and that treats the rarest disease imaginable as a starting point rather than a limit.
